⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNPR News
Monopar Therapeutics Inc. Common Stock
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR
Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
KURA
BMY
IPHA
MRK
MNPR
JAZZ
MOLN
LLY
GSK
AGEN
PFE
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR
Form 8-K
sec.gov
MNPR
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR